One2Treat offers a paradigm shift within clinical development with a unique method of evaluation of the Net Treatment Benefit

Including multiple criteria within a single primary endpoint, our approach:

• reduces sample sizes in clinical trials, cutting clinical research timelines
• gives each patient access to the treatment which best meets their needs.

One2Treat’s solution ensures the medical need and potential of every treatment is explored in full. It showcases valuable additional treatment benefits to help strengthen drug development, regulatory submission and post-regulatory market access.

Pascal Piedbois, Chief Medical Officer, tells us more about ‘Shifting the paradigm of drug development with more patient-centric clinical trials’. He does so together with Jean-Christophe Chiem, Product Manager at One2Treat.

Current clinical trials may fail in capturing all the facets of a treatment that matters for the patients. One2Treat Solutions empower patient representatives and clinicians to shape clinical trials by prioritizing outcomes that matter most to them. Through scenario-based decision-making, this solution refines individual preferences and creates a tailored list of key outcomes. By integrating these priorities into trial design, One2Treat ensures that drug development aligns with patients’ needs and regulatory guidance, redefining the future of patient-focused clinical research.

You can find the presentation here: Shifting the paradigm of drug development with more patient-centric clinical trials >>